Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹260 Cr
Revenue (TTM)
₹46 Cr
Net Profit (TTM)
₹3 Cr
ROE
6 %
ROCE
11.5 %
P/E Ratio
78.7
P/B Ratio
2.6
Industry P/E
26.59
EV/EBITDA
14.6
Div. Yield
0 %
Debt to Equity
0
Book Value
₹16.1
EPS
₹0.6
Face value
10
Shares outstanding
61,030,568
CFO
₹43.31 Cr
EBITDA
₹55.12 Cr
Net Profit
₹3.25 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zenotech Lab
| -7.7 | -5.5 | -7.7 | -20.2 | -3.2 | 3.5 | 2.8 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Zenotech Lab
| -35.5 | 7.3 | 2.7 | 6.1 | 66.1 | 48.8 | -30.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zenotech Lab
|
42.6 | 260.2 | 45.9 | 3.3 | 14.0 | 3.7 | 78.7 | 2.6 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,499.2 | 9,167.3 | 1,196.4 | 149.4 | -- | 27.5 | 61.3 | 13.1 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Zenotech Laboratories Limited operates as a pharmaceutical specialty generic injectables company in India. The company manufactures oncology, biotechnology, and general injectable products, such as granulocyte-colony stimulating factor (GCSF) and... granulocyte-macrophage colony-stimulating factor (GMCSF). Its injectable product portfolio primarily serves therapy areas, such as oncology and anesthesiology. The company was formerly known as Sunline Technologies Limited and changed its name to Zenotech Laboratories Limited in August 2004. Zenotech Laboratories Limited was incorporated in 1989 and is based in Hyderabad, India. Read more
Incorporated
1989
Chairman
--
Managing Director
--
Group
Sun Pharma
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Zenotech Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Zenotech Laboratories Ltd is ₹42.63 (BSE) as of 02-Apr-2026 IST. Zenotech Laboratories Ltd has given a return of -3.24% in the last 3 years.
The P/E ratio of Zenotech Laboratories Ltd is 78.70 times as on 02-Apr-2026, a 196 premium to its peers’ median range of 26.59 times.
The P/B ratio of Zenotech Laboratories Ltd is 2.65 times as on 02-Apr-2026, a 41 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
56.45
|
3.30
|
|
2024
|
43.47
|
3.98
|
|
2023
|
24.79
|
3.49
|
|
2022
|
13.86
|
4.35
|
|
2021
|
0.00
|
4.41
|
The 52-week high and low of Zenotech Laboratories Ltd are Rs 72.87 and Rs 33.55 as of 03-Apr-2026.
Zenotech Laboratories Ltd has a market capitalisation of ₹ 260 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Zenotech Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹4.93
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.